Skip to Content
Merck
CN
All Photos(2)

Documents

217708

Sigma-Aldrich

ML141

≥99% (HPLC), solid, Cdc42/Rac1 GTPase inhibitor, Calbiochem®

Synonym(s):

Cdc42/Rac1 GTPase Inhibitor, ML141, CDC42 GTPase Inhibitor II, CDC42 Inhibitor II, Rac1 Inhibitor V, Rac1 GTPase Inhibitor II, CID2950007, (±)-4-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl))-benzenesulfonamide, (±)-4-(4,5-Dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyra, CDC42 GTPase Inhibitor II, CDC42 Inhibitor II, Rac1 Inhibitor V, Rac1 GTPase Inhibitor II, CID2950007, (±)-4-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl))-benzenesulfonamide, (±)-4-(4,5-Dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyraz

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C22H21N3O3S
CAS Number:
71203-35-5
Molecular Weight:
407.49
MDL number:
MFCD05987165
UNSPSC Code:
12352200
NACRES:
NA.28

product name

Cdc42/Rac1 GTPase Inhibitor, ML141, The Cdc42/Rac1 GTPase Inhibitor, ML141 controls the biological activity of Cdc42/Rac1 GTPase. This small molecule/inhibitor is primarily used for Membrane applications.

Quality Level

100

Assay

≥99% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

yellow-white

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

−20°C

InChI

1S/C22H21N3O3S/c1-28-19-11-7-17(8-12-19)22-15-21(16-5-3-2-4-6-16)24-25(22)18-9-13-20(14-10-18)29(23,26)27/h2-14,22H,15H2,1H3,(H2,23,26,27)

InChI key

QBNZBMVRFYREHK-UHFFFAOYSA-N

General description

A cell-permeable, allosteric, trisubstituted dihydropyrazolyl compound that acts as a potent, selective, reversible and non-competitive inhibitor of Cdc42 GTPases (IC50 = 0.2, 2.6 and 5.4 µM against nucleotide depleted Cdc42-wt, Cdc42-wt and Cdc42 activated mutant, respectively) with excellent selectivity over Rho family GTPases (IC50 >100 µM for Ras-wt, Ras activated mutant, Rab7-wt, Rab2a-wt, Rac1-wt and Rac1 activated mutant). Shown to efficiently block Cdc42 association with GTPγS and PAK-PBD, and decrease GTP-Cdc42 (>95%) and GTP-Rac1 (≥40%) contents in EGF-stimulated 3T3 cells, and inhibit Bradykinin (Cat. No. 05-23-0500)-induced filopodia formation in 3T3 cells at 10 µM.

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Hong, L., et al. 2012. J. Biol. Chem.in press.
Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.2010 Feb 27. (http://www.ncbi.nlm.nih.gov/books/NBK51965/)

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chang Liu et al.
Acta biomaterialia, 155, 167-181 (2022-11-13)
3D in vitro tumor models have recently been investigated as they can recapitulate key features in the tumor microenvironment. Reconstruction of a biomimetic scaffold is critical in these models. However, most current methods focus on modulating local properties, e.g. micro-
Meiwan Cao et al.
Redox report : communications in free radical research, 27(1), 167-175 (2022-08-09)
The number of neutrophils is significantly reduced in myelodysplastic syndrome (MDS), but the molecular basis remains unclear. We recently found that miR-34a was significantly increased in MDS neutrophils. Therefore, this study aims to clarify the effects of aberrant miR-34a expression
Golnaz Morad et al.
International journal of molecular sciences, 21(11) (2020-06-03)
Breast cancer brain metastasis is a major clinical challenge and is associated with a dismal prognosis. Understanding the mechanisms underlying the early stages of brain metastasis can provide opportunities to develop efficient diagnostics and therapeutics for this significant clinical challenge.
Jun Matsuda et al.
Journal of the American Society of Nephrology : JASN, 31(5), 996-1008 (2020-03-20)
Previous studies showed that Cdc42, a member of the prototypical Rho family of small GTPases and a regulator of the actin cytoskeleton, is critical for the normal development and health of podocytes. However, upstream regulatory mechanisms for Cdc42 activity in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service